A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer

Oncotarget

Volumn 7, Issue 23, 2016, Pages 34277-34287

  Liu, Ben ^a,b   Zhang, Xining ^a,b   Song, Fengju ^a,b   Liu, Qun ^a,b   Dai, Hongji ^a,b   Zheng, Hong ^a,b   Cui, Ping ^a,b   Zhang, Lina ^a,b   Zhang, Wei ^c,d   Chen, Kexin ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS   (United States)

^d WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Breast cancer; Prognosis; Rs16917496; SET8; Single nucleotide polymorphisms (SNP)

Indexed keywords

3' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SET8 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL ANALYSIS; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY;

HISTONE LYSINE METHYLTRANSFERASE; SETD8 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84973662108     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9099     Document Type: Article

References (43)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Chen W, Zheng R, Zeng H, Zhang S. The updated incidences and mortalities of major cancers in China, 2011. Chin J Cancer. 2015; 34:53.
3. Yu ZB, Li Z, Jolicoeur N, Zhang LH, Fortin Y, Wang E, Wu MQ, Shen SH. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic acids research. 2007; 35:4535-4541.
4. Yu JC, Ding SL, Chang CH, Kuo SH, Chen ST, Hsu GC, Hsu HM, Hou MF, Jung LY, Cheng CW, Wu PE, Shen CY. Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes. Carcinogenesis. 2009; 30:1562-1570.
5. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Forsti A, Hemminki K, Canzian F, Landi S. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis. 2008; 29:579-584.
6. Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis. 2008; 29:1306-1311.
7. Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, Majzoub K, Rivas GE, Alluin J, Rossi JJ, Krontiris TG, Weitzel J, Daly MB, Benson AB, et al. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res. 2009; 69:7459-7465.
8. Martinez E, Silvy F, Fina F, Bartoli M, Krahn M, Barlesi F, Figarella-Branger D, Iovanna J, Laugier R, Ouaissi M, Lombardo D, Mas E. Rs488087 single nucleotide polymorphism as predictive risk factor for pancreatic cancers. Oncotarget. 2015. doi: 10.18632/oncotarget.5627.
9. He N, Zheng H, Li P, Zhao Y, Zhang W, Song F, Chen K. miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk. PloS one. 2014; 9:e102093.
10. Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu H, Liu P, Hao X, Zhang W, Chen K. Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A. 2011; 108: 13653-13658.
11. Xiao B, Jing C, Kelly G, Walker PA, Muskett FW, Frenkiel TA, Martin SR, Sarma K, Reinberg D, Gamblin SJ, Wilson JR. Specificity and mechanism of the histone methyltransferase Pr-Set7. Genes Dev. 2005; 19:1444-1454.
12. Houston SI, McManus KJ, Adams MM, Sims JK, Carpenter PB, Hendzel MJ, Rice JC. Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability. J Biol Chem. 2008; 283:19478-19488.
13. Wu S, Wang W, Kong X, Congdon LM, Yokomori K, Kirschner MW, Rice JC. Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dev. 2010; 24:2531-2542.
14. Congdon LM, Houston SI, Veerappan CS, Spektor TM, Rice JC. PR-Set7-Mediated Monomethylation of Histone H4 Lysine 20 at Specific Genomic Regions Induces Transcriptional Repression. J Cell Biochem. 2010; 110:609-619.
15. Oda H, Hubner MR, Beck DB, Vermeulen M, Hurwitz J, Spector DL, Reinberg D. Regulation of the histone H4 monomethylase PR-Set7 by CRL4(Cdt2)-mediated PCNAdependent degradation during DNA damage. Mol Cell. 2010; 40:364-376.
16. Yao L, Li Y, Du F, Han X, Li X, Niu Y, Ren S, Sun Y. Histone H4 Lys 20 methyltransferase SET8 promotes androgen receptor-mediated transcription activation in prostate cancer. Biochem Biophys Res Commun. 2014.
17. Yang F, Sun L, Li Q, Han X, Lei L, Zhang H, Shang Y. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 2012; 31:110-123.
18. Takawa M, Cho HS, Hayami S, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Maejima K, Ueda K, Masuda A, Dohmae N, Field HI, Tsunoda T, et al. Histone Lysine Methyltransferase SETD8 Promotes Carcinogenesis by Deregulating PCNA Expression. Cancer Res. 2012; 72:3217-3227.
19. Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, Dutta S, Appella E, Gozani O. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 2007; 27:636-646.
20. Li Z, Nie F, Wang S, Li L. Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc Natl Acad Sci U S A. 2011; 108:3116-3123.
21. Li Y, Sun L, Zhang Y, Wang D, Wang F, Liang J, Gui B, Shang Y. The histone modifications governing TFF1 transcription mediated by estrogen receptor. J Biol Chem. 2011; 286:13925-13936.
22. Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L, Calin GA, Hao X, Wei Q, Zhang W, Chen K. An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res. 2009; 15:6292-6300.
23. Yang S, Guo H, Wei B, Zhu S, Cai Y, Jiang P, Tang J. Association of miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population. Acta Biochim Biophys Sin (Shanghai). 2014; 46:149-154.
24. Wang C, Guo Z, Wu C, Li Y, Kang S. A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer. Cancer Genet. 2012; 205:373-376.
25. Hashemi M, Sheybani-Nasab M, Naderi M, Roodbari F, Taheri M. Association of functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report. Tumour Biol. 2014.
26. Yang SD, Cai YL, Jiang P, Li W, Tang JX. Association of a miR-502-Binding Site Single Nucleotide Polymorphism in the 3'-Untranslated Region of SET8 and the TP53 Codon 72 Polymorphism with Cervical Cancer in the Chinese Population. Asian Pac J Cancer Prev. 2014; 15:6505-6510.
27. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, Ravagnani F, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010; 70:2789-2798.
28. Ding C, Li R, Peng J, Li S, Guo Z. A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer. Exp Ther Med. 2012; 3:689-692.
29. Guo Z, Wu C, Wang X, Wang C, Zhang R, Shan B. A polymorphism at the miR-502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome. Int J Cancer. 2012; 131:1318-1322.
30. Diao L, Su H, Wei G, Li T, Gao Y, Zhao G, Guo Z. Prognostic value of microRNA 502 binding site SNP in the 3'-untranslated region of the SET8 gene in patients with non-Hodgkin's lymphoma. Tumori. 2014; 100:553-558.
31. Xu J, Yin Z, Gao W, Liu L, Yin Y, Liu P, Shu Y. Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. PloS one. 2013; 8:e77024.
32. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, ZhaoK. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008; 40:897-903.
33. Knijnenburg TA, Bismeijer T, Wessels LF, Shmulevich I. A multilevel pan-cancer map links gene mutations to cancer hallmarks. Chin J Cancer. 2015; 34:48.
34. Kleer CG, Cao Q, Varambally S, Shen RL, Ota L, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100:11606-11611.
35. Beguelin W, Popovic R, Teater M, Jiang YW, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang HK, Zheng YP, et al. EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer cell. 2013; 23:677-692.
36. Chiba T, Saito T, Yuki K, Zen Y, Koide S, Kanogawa N, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Otsuka M, Miyazaki M, et al. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. Int J Cancer. 2015; 136:289-298.
37. Baker T, Nerle S, Pritchard J, Zhao B, Rivera VM, Garner A, Gonzalvez F. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget. 2015; 6:32646-32655. doi: 10.18632/oncotarget.5066.
38. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, et al. Selective killing of mixed lineage leukemia cells by a potent smallmolecule DOT1L inhibitor. Cancer cell. 2011; 20:53-65.
39. Wee S, Dhanak D, Li H, Armstrong SA, Copeland RA, Sims R, Baylin SB, Liu XS, Schweizer L. Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci. 2014; 1309:30-36.
40. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007; 21:1050-1063.
41. Bullard JH, Purdom E, Hansen KD, Dudoit S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC bioinformatics. 2010; 11:94.
42. Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015; 12:697.
43. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA. 2004; 10:1507-1517.